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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.026Chronic renal disease (CRD) accelerates the development of atherosclerosis. The potent protease
cathepsin S cleaves elastin and generates bioactive elastin peptides, thus promoting vascular inﬂam-
mation and calciﬁcation. We hypothesized that selective cathepsin S inhibition attenuates atherogenesis
in hypercholesterolemic mice with CRD. CRD was induced by 5/6 nephrectomy in high-fat high-cholesterol
fed apolipoprotein Eedeﬁcient mice. CRD mice received a diet admixed with 6.6 or 60 mg/kg of the potent
and selective cathepsin S inhibitor RO5444101 or a control diet. CRD mice had signiﬁcantly higher plasma
levels of osteopontin, osteocalcin, and osteoprotegerin (204%, 148%, and 55%, respectively; P< 0.05),
which were inhibited by RO5444101 (60%, 40%, and 36%, respectively; P < 0.05). Near-infrared ﬂuo-
rescence molecular imaging revealed a signiﬁcant reduction in cathepsin activity in treated mice.
RO5444101 decreased osteogenic activity. Histologic assessment in atherosclerotic plaque demonstrated
that RO5444101 reduced immunoreactive cathepsin S (P< 0.05), elastin degradation (PZ 0.01), plaque
size (PZ 0.01), macrophage accumulation (P < 0.01), growth differentiation factor-15 (PZ 0.0001),
and calciﬁcation (alkaline phosphatase activity, P< 0.01; osteocalcin, P< 0.05). Furthermore, cathepsin
S inhibitor or siRNA signiﬁcantly decreased expression of growth differentiation factor-15 and monocyte
chemotactic protein-1 in a murine macrophage cell line and human primary macrophages. Systemic
inhibition of cathepsin S attenuates the progression of atherosclerotic lesions in 5/6 nephrectomized
mice, serving as a potential treatment for atherosclerosis in patients with CRD. (Am J Pathol 2015, 185:
1156e1166; http://dx.doi.org/10.1016/j.ajpath.2014.11.026)Supported by investigator-initiated research grant 2010A052417 from
Hoffmann-La Roche Ltd. (E.A.) and by NIH grants R01HL114805 and
R01HL109506 (E.A.), R01HL107550 (M.A.), and R01HL80472 (P.L.).
Disclosures: S.G., J.F., W.H., and G.H. are employees of Hoffmann-La
Roche Ltd., which also funded parts of this research.Half of all patients with chronic renal disease (CRD) die of
cardiovascular causes.1,2 Patients with early stages of CRD
who are not undergoing dialysis have cardiovascular disease
(CVD) risk similar to that of patients with established coronary
artery disease,3 whereas patients with end-stage renal disease,
treated by dialysis, have an approximately 30 times greater
CVD risk than the general population.4,5 Despite being at
elevated risk for CVD, patients with CRD have experienced
limited beneﬁts from statin treatment alone.6,7 Hence, the need
is emerging to investigate the mechanisms responsible for
CVD in CRD patients to develop effective new therapies.
Arterial inﬂammation is a key facet of atherosclerotic lesion
initiation and progression.8,9 Several molecular mechanismsstigative Pathology.
.participate in the response to injuries at the vascular wall and
in the formation and progression of atherosclerotic lesions.10
Chronic inﬂammation likely accelerates atherosclerosis in
patients with CRD,11 and the combination of chronic inﬂam-
mation and an imbalance in the calcium phosphate serum level
in these patients exacerbates these processes.12,13 In addition,
CRD patients receiving hemodialysis have elevated levels of
Cathepsin S Inhibition in Atherosclerosiscirculating proinﬂammatory cytokines,14 which can initiate
and perpetuate the inﬂammation-calciﬁcation loop.
Cathepsin S plays a critical role in vascular inﬂammation
and calciﬁcation. Monocyte-derived macrophages that
mediate vascular inﬂammation express and secrete the
cysteine protease cathepsin S.15 At the basal membrane of
the blood vessels, secreted cathepsin S cleaves several
extracellular matrix proteins, including laminin, collagen,
and, preferentially, elastin, which generate bioactive
elastin peptides.16,17 Elastin-derived peptides and frag-
ments, also known as matrikines, can incite inﬂammation.
Elastin peptides stimulate macrophage chemotaxis18 and
promote vascular inﬂammation and calciﬁcation.19 In
addition, cathepsin S co-localizes with regions of increased
elastin breaks in atherosclerotic plaques.20
We previously reported that cathepsin S deﬁciency leads
to reduced elastolytic activity and decreased vascular
inﬂammation and calciﬁcation in the arteries of hyper-
cholesterolemic mice with experimental CRD, providing
in vivo evidence implicating cathepsin Seinduced elas-
tolysis in arterial and aortic valve calciﬁcation.21 To seek a
clinically translatable proof of concept, the present study
tested the hypothesis that treatment with a highly selective
cathepsin S inhibitor attenuates inﬂammation and athero-
sclerotic lesion formation in the arteries of hypercholes-
terolemic mice with CRD.
Materials and Methods
Animal Protocol
Male 10-week-old Apoe/ mice (N Z 60) from The
Jackson Laboratory (Bar Harbor, ME) were fed a high-fat
high-cholesterol diet (Teklad TD.88137; Harlan Labora-
tories, Indianapolis, IN) for 10 weeks. At 20 weeks of age,
mice were randomized either to continue with the diet (nZ
15) or to undergo 5/6 nephrectomy (n Z 45). CRD mice
were then treated with 6.6 or 60 mg/kg of RO5444101, a
highly potent and selective cathepsin S inhibitor (Hoffmann-
La Roche, Basel, Switzerland) (nZ 15 per group), admixed
with the high-fat high-cholesterol diet for an additional 10
weeks. The Harvard Medical School Standing Committee
on Animals approved all the animal studies.
Cells and Reagents
Human peripheral blood mononuclear cells (PBMCs) were
isolated by centrifugation in Ficoll-Hypaque (Sigma-
Aldrich, St. Louis, MO) and adherence. Cells were cultured
for 10 days in RPMI 1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 5% heat-inactivated human serum,
2 mmol/L L-glutamine, 100 mg/mL penicillin, and 100 U/
mL streptomycin to differentiate into macrophages. Murine
macrophage-like RAW264.7 cells were purchased from
ATCC (Manassas, VA) and grown in Dulbecco’s modiﬁed
Eagle’s medium with 10% fetal bovine serum.The American Journal of Pathology - ajp.amjpathol.orgSurgically Induced CRD
We used an established model to induce chronic renal
failure by controlling the amount of kidney mass removed.21
This procedure includes two steps to create uremia.21,22
First, we performed 2/3 nephrectomy, removing the top
one-third and bottom one-third of the left kidney. Then,
after 7 days of healing, the right kidney was removed.
Molecular Imaging of Cathepsin Activity and
Osteogenesis
Twenty-four hours before imaging, mice received simulta-
neous i.v. injections of two spectrally distinct molecular
imaging agents: a protease-activatable, pan-cathepsin ﬂuo-
rescent agent (ProSense 750; PerkinElmer, Waltham, MA)
and a bisphosphonate-conjugated calcium tracer (OsteoSense
680; PerkinElmer). Dual-channel (633 nm for excitation and
748 nm for emission) in vivo near-infrared ﬂuorescence
(NIRF) of carotid arteries was acquired using a laser scanning
multicolor ﬂuorescence microscope (Olympus Corp, Tokyo,
Japan), as previously described elsewhere.23,24 For ex vivo
NIRF reﬂectance imaging, we perfused the heart with saline
solution to ﬂush out blood. Aortas and arteries were dissected
and then were imaged using an NIRF reﬂectance imaging
system (Image Station 4000MM; Eastman Kodak Co., New
Haven, CT). Image stacks were processed and analyzed using
ImageJ software version 1.41 (NIH, Bethesda, MD). Mice
were then sacriﬁced for correlative histologic analyses of the
aorta and arteries.
Quantiﬁcation of Compound Plasma Levels and p10
Accumulation in Spleens
Male 8-week-old wild-type mice (N Z 8; Charles River
Laboratories, Sulzfeld, Germany) received RO5444101, and
terminal blood samples were collected at seven different time
points in precooled EDTA-coated tubes. The samples were
kept on ice and immediately centrifuged at 4C to obtain
plasma. Quantiﬁcation of compound levels in plasma was
performed by liquid chromatographyetandem mass spec-
trometry analysis. Increased p10 was conﬁrmed in spleens,
which were homogenized in radioimmunoprecipitation assay
buffer with protease inhibitors. Lysates were electrophoresed,
and proteins were transferred to polyvinylidene diﬂuoride
membrane. Membrane was incubated with CD74 primary
antibody (BD Pharmingen, Heidelberg, Germany) and then
with anti-rabbit secondary antibody. The membrane was
developed by Western blot analysis (GE Healthcare, Buck-
inghamshire, UK).
Quantiﬁcation of Blood Proteins
Blood was collected via the inferior vena cava and was
spun in a refrigerated centrifuge; serum was stored at
80C. Serum levels of osteogenic markers, including1157
Figure 1 Pharmacology of RO5444101, a spe-
ciﬁc inhibitor of cathepsin S. A: The structure of
the selective cathepsin S inhibitor RO5444101. B:
Human B cells isolated from peripheral blood
mononuclear cells were treated with increasing
concentrations of RO5444101, followed by Western
blot analysis to quantify accumulation of p10. C:
Effects of cathepsin S compound on p10 accumu-
lation in vivo. Signiﬁcant p10 accumulation was
observed at a 10-mg/kg dose. D: The plasma
concentration of RO5444101 compound in rela-
tionship to p10 accumulation. The green line
depicts the p10 elevation depending on drug
plasma concentration (plasma exposure); red line,
the half maximal concentration of drug in plasma
to achieve p10 elevation (EC50); blue plus signs,
measurements for the green curve. Data represent
means  SD. *P < 0.05.
Figueiredo et albone gamma-carboxylglutamate (gla) protein or osteocalcin,
secreted phosphoprotein 1 or osteopontin, and osteoprotegerin
or tumor necrosis factor receptor superfamily, member 11b,
were measured by sandwich enzyme-linked immunosorbent
assay kits (Millipore, Billerica, MA).Histopathologic Assessment
Tissue samples were frozen in optimum cutting temperature
compound (Sakura Finetek, Torrence, CA), and 6-mm serial
sections were cut and stained with hematoxylin and eosin for
general morphologic evaluation. Alkaline phosphatase
activity was detected on cryosections (alkaline phosphatase
substrate kit; Vector Laboratories, Burlingame, CA). Van
Gieson stain was used to assess elastin. Immunohistochem-
ical analysis for macrophages (anti-mouse mac3; BD Bio-
sciences, San Jose, CA), cathepsin S (anti-mouse cathepsin
S; Santa Cruz Biotechnology, Santa Cruz, CA), osteocalcin
(goat anti-mouse polyclonal antibody; Serotech, Dusseldorf,
Germany), and growth differentiation factor-15 (GDF15)
(rabbit antieGdf-15 polyclonal antibody; Bioss Antibodies,
Woburn, MA) was performed using the avidin-biotin
peroxidase method. Images were captured and processed
using an Eclipse 80i microscope (Nikon Instruments, Mel-
ville, NY). Serial or adjacent sections were used for analyses
of quantitative data. Double immunoﬂuorescence stainingTable 1 Species and Protease Selectivity of the Cathepsin S Inhibitor
RO compound
50% Inhibito
Human CatS Mouse CatS Dog CatS Rabbit C
RO5444101 0.2 0.3 7.9 0.4
In vitro effects of RO5444101 on recombinant cathepsin S from different specie
selectivity over other cathepsins in humans. This compound also shows high pot
Cat, cathepsin.
1158was performed using cathepsin S antibodies and either mac3
or a-smooth muscle actin (clone 1A4; Sigma-Aldrich).
Sections were counterstained with DAPI to visualize
nuclei. Images were processed using an Eclipse confocal
microscope system (Nikon Instruments).
siRNA Transfection
RAW264.7 cells were transfected with 200 nmol/L siRNA
against cathepsin S or control scrambled nontargeting
siRNA (Dharmacon, Lafayette, CO) using Lipofectamine
2000 (Invitrogen) for 48 hours before experiments,
following the manufacturer’s protocols. By this method, the
silencing efﬁciency was consistently >90%.
Quantiﬁcation of Gene Expression by Quantitative
RT-PCR
Total RNA from human and murine macrophages was isolated
using an RNeasy kit (Qiagen GmbH, Hilden, Germany) and
was reverse transcribed by SuperScript II Reverse Transcriptase
(Invitrogen) and oligo (dT) primers. Quantitative PCR was
performed in the MyiQ single-color real-time PCR detection
system (Bio-Rad Laboratories, Hercules, CA). The following
primers from Integrated DNA Technologies (Coralville, IA)
were used: hGDF-15: forward 50-GACCCTCAGAGTTG-RO5444101
ry concentration (nmol/L)
atS Human CatV or L2 Human CatK, CatL, CatC, CatX, CatH
2849.0 All >25,000
s and various human proteinases. The compound showed high potency and
ency against cathepsin S in animals.
ajp.amjpathol.org - The American Journal of Pathology
Table 2 EC50 Values of the Cathepsin S Inhibitor RO5444101
RO
compound
EC50 (nmol/L)
D1 D2 D3 D4 D5 D6 Mean  SD
RO5444101 328.5 174.9 178.9 170.9 164.3 118.0 189.3  71.7
D, donor.
Cathepsin S Inhibition in AtherosclerosisCACTCC-30 and reverse 50-GCCTGGTTAGCAGGTCCTC-
30; mGDF-15: forward 50-AGCTGCTACTCCGCGTCAA-30
and reverse 50-GTAAGCGCAGTTCCAGCTG-30; hMCP-1/
CCL2: forward 50-CAGCCAGATGCAATCAATGCC-30 and
reverse 50-TGGAATCCTGAACCCACTTCT-30; and mMCP-
1/CCL2: forward 50-AGGTCCCTGTCATGCTTCTG-30 and
reverse 50-TCTGGACCCATTCCTTCTTG-30. The mRNA
levels of the various genes tested were normalized to glycer-
aldehyde-3-phosphate dehydrogenase levels for human sam-
ples and to b-actin levels for murine samples.
Experiments on the Pharmacology of Cathepsin S
Inhibitor and p10 Assay
Enzymatic activity was measured by observing the increase
in ﬂuorescence intensity caused by cleavage of a peptide
substrate containing a ﬂuorophore, the emission of which is
quenched in the intact peptide. The assay buffer consisted of
100 mmol/L potassium phosphate, pH 6.5, 5 mmol/L EDTA-
Na, 0.001% Triton X-100 (Roche Diagnostics GmbH,
Mannheim, Germany), and 5 mmol/L dithiothreitol. The
enzymes (all at 1 nmol/L) used were as follows: human and
mouse cathepsins S, K, L, and B were measured. Substrate
(20 mmol/L): Z-Val-Val-Arg-AMC, except for cathepsin K,
which uses Z-Leu-Arg-AMC (both from Bachem, Buben-
dorf, Sweden). Excitation was 360 nm, and emission was 465
nm. Enzyme was added to the substance dilutions in 96-well
microtiter plates, and the reaction was started with substrate.
Fluorescence emission was measured over 20 minutes.
Invariant chain p10 accumulation was detected in human
B cells by Western blot analysis. B cells were puriﬁed from
human PBMCs, with further puriﬁcation of B cells using a
CD19þ afﬁnity bead puriﬁcation kit (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). Cells were stimulated with
indicated concentrations of RO5444101 for 16 hours andTable 3 Treatment with Cathepsin S Inhibitor Decreases Plasma Levels
with CRD Compared with Those without Treatment
Mouse group Osteocalcin (ng/mL)
Apoe/ 64.6  28.1
Apoe/ CRD 161.3  50.5*y
Apoe/ CRD þ 6.6 mg/kg 113.6  61.6*
Apoe/ CRD þ 60 mg/kg 96.4  20.1y
Blood samples were collected from Apoe/ mice at the end of the treatment
enzyme-linked immunosorbent assay.
*P < 0.05 between the low-dose treatment group (6.6 mg/kg) and the CRD gr
yP < 0.05 between the high-dose treatment group (60 mg/kg) and the CRD gr
CRD, chronic renal disease.
The American Journal of Pathology - ajp.amjpathol.orgthen were homogenized in radioimmunoprecipitation assay
buffer with protease inhibitors. Lysates were electro-
phoresed, and proteins were transferred to polyvinylidene
diﬂuoride membrane. Membrane was incubated with CD74
primary antibody Pin.1 and goat anti-mouse IgGehorser-
adish peroxidase (Art. 32430; Pierce Biotechnology, Rock-
ford, IL). The membrane was developed by Western blot
analysis (GE Healthcare).
Statistical Analysis
Data are presented as means  SEM. Analysis of variance
and Student’s t-test were performed using GraphPad
Prism software version 5.0 (GraphPad Software Inc., San
Diego, CA).
Results
Structure and Pharmacology of a Speciﬁc Cathepsin S
Inhibitor
This study used RO5444101, an inhibitor with high speciﬁcity
to cathepsin S but not other cathepsins (Figure 1A). This
compound inhibits the active site of cathepsin S with high
potency (inhibitory constant was 0.13 nmol/L using an in vitro
peptide cleavage assay) and good selectivity over other
cathepsins (B, K, L, C, H, V, and X) or noncysteine proteases,
tested to concentrations of up to 10 mmol/L (Table 1). The
cellular activity of the compound was tested in assays of an-
tigen presentation in human B cells. Cathepsin S cleaves
critically the invariant chain, a chaperone of the major histo-
compatibility complex class II molecule. Inhibition of
cathepsin S in antigen-presenting cells results in the accumu-
lation of an intermediate of the invariant chaindp10das
determined by Western blot analysis (Figure 1B). The mean
EC50 of RO5444101 was determined to be 189.3 nmol/L
(Table 2).We also tested the effects of this compound in mice
and observed that it signiﬁcantly induced p10 accumulation
in spleen extracts, demonstrating its in vivo efﬁcacy
(Figure 1, C and D). Reduced invariant cleavage, in turn,
reduces surface major histocompatibility complex class II
levels and the antigen-induced cytokine response in PBMCs.
Inhibition of cathepsin S is, therefore, of great interest inof Osteocalcin, Osteopontin, and Osteoprotegerin in Apoe/ Mice
Osteopontin (ng/mL) Osteoprotegerin (ng/mL)
1079.4  300.1 1.8  0.5
3275.1  1181.0*y 2.8  0.9*y
1832.7  1109.0* 2.2  0.7*
1294.3  478.2y 1.8  0.4y
period, and plasma levels of the osteogenic cytokines were measured by
oup.
oup.
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Figure 2 Effects of the cathepsin S inhibitor RO5444101 on cathepsin expression and activity in arteries of Apoe/ mice with chronic renal disease (CRD).
A:Representativemicroscopy images of cathepsin activity in the carotid arteries of live animals.B andC: Cathepsin activity in the entire aorta and carotid arteries using ex
vivo ﬂuorescence reﬂectance imaging. Note an increased cathepsin activity signal in the carotid arteries and abdominal aorta of Apoe/ mice with CRD, which is
diminished in the treated groups (white arrows). Quantiﬁcation (B) and representative ex vivo near-infrared ﬂuorescent reﬂectance images (C). D and E: Representative
immunohistochemical staining images of cathepsin S in the aortic arch. F and G: Elastin ﬁber breaks (yellow arrows) detected by van Gieson staining (F) and quantiﬁed
elastinﬁber breaks (G) in the lesser curvatureof theaortic arch.Hand I:Cathepsin Sco-localizationwithmacrophages (whitearrows) and smoothmuscle cells inApoe/
mice with CRD. H, inset: Enlarged macrophage co-expressing cathepsin S. L indicates lumen. Data represent means SD. *P< 0.05. Original magniﬁcation:400.
Figueiredo et alchronic inﬂammatory diseases because it may reduce tissue
damage and dampen the generation of autoimmunity.
Overall, RO5444101 compound shows good bioavailability
and pharmacokinetic properties in mice and cynomolgus
monkeys, making it an attractive small molecule inhibitor to
study the function of cathepsin S in the context of chronic
inﬂammatory diseases, including atherosclerosis.1160Treatment with a Speciﬁc Cathepsin S Inhibitor
Attenuates the Increase in Plasma Levels of
Osteogenic Markers in Apoe/ Mice with CRD
Plasma levels of osteocalcin [or bone gamma-carboxyglutamate
(gla) protein], osteopontin (or secreted phosphoprotein 1), and
osteoprotegerin (or tumor necrosis factor receptor superfamily,ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Cathepsin S inhibitor RO5444101 decreases plaque size, macrophage accumulation, and growth differentiation factor-15 (GDF15) expression in
the atherosclerotic arteries of Apoe/ mice with chronic renal disease (CRD). A and D: Quantiﬁcation of atherosclerotic plaque size at the lesser curvature of
the aortic arch using hematoxylin and eosin (H&E) staining. B and E: Mac3 staining in the aortic arch (B) shows macrophage accumulation on representative
images; quantitative analysis of Mac3 staining (E). C and F: Immunohistochemical staining for a proinﬂammatory cytokine, GDF15, in the aortic arch (C) and
its quantiﬁcation (F). Data represent means  SD. *P < 0.05, ***P < 0.001.
Cathepsin S Inhibition in Atherosclerosismember 11b) increased in mice with CRD after 5/6 nephrec-
tomy (Table 3). Treatment of CRD mice with the cathepsin S
inhibitor RO5444101 attenuated these elevations. We observed
dose-dependent decreases in plasma levels of osteocalcin
(P < 0.05, 6 mg/kg; P < 0.001, 60 mg/kg), osteopontin
(P < 0.05, 6 mg/kg; P< 0.01, 60 mg/kg), and osteoprotegerin
(P< 0.05, 6mg/kg;PZ 0.001, 60mg/kg) comparedwithCRD
alone (Table 3). These results indicate that RO5444101 at 60
mg/kg reduced CRD-associated elevation of these proin-
ﬂammatory and pro-osteogenic markers to normal levels.
RO5444101 Treatment Reduces Arterial Cathepsin
Activity in CRD Mice
Intravital multichannel, high-resolution laser scanning ﬂuo-
rescence microscopy visualized in vivo real-time overallThe American Journal of Pathology - ajp.amjpathol.orgcathepsin activity with ProSense 750, a protease-activatable
NIRF in vivo imaging agent that is activated by cathepsins,
including cathepsins B, L, and S. Mice with CRD showed
enhanced proteolytic signals in the carotid arteries compared
with control animals, an effect that cathepsin S inhibitor
treatment limited (Figure 2A). In addition, we used ex vivo
macroscopic ﬂuorescence reﬂectance imaging to map
cathepsin activity in the aorta and carotid arteries. We
observed a signiﬁcant reduction in ProSense 750 signals in
mice treated with RO5444101 (P < 0.01, 60 mg/kg dose
versus CRD group) (Figure 2, B and C). Immunohisto-
chemical analysis showed that cathepsin S inhibitor treatment
attenuated CRD-induced accumulation of cathepsin S in the
atherosclerotic plaques (Figure 2, D and E). Together, the
molecular imaging and immunohistochemical analysis
results suggested that cathepsin S inhibitor treatment reduced1161
Figure 4 Cathepsin S inhibition decreases osteogenic activity in the atherosclerotic aorta and carotid arteries of Apoe/ mice with chronic renal
disease (CRD). A: Representative microscopic images of vascular calciﬁcation in the carotid arteries using a calcium-sensitive tracer (OsteoSense 680) in
live animals. B and C: Osteogenic activity (OsteoSense 680) in the entire aorta and carotid arteries using ex vivo ﬂuorescence reﬂectance imaging. Note
an increased osteogenic activity signal in the carotid arteries and abdominal aorta of Apoe/ mice with CRD, which is diminished in the treated groups
(arrows). Quantiﬁcation (B) and representative ex vivo near-infrared ﬂuorescent reﬂectance images (C). D and E: The activity of alkaline phosphatase
(ALP) in the aortic arch. F and G: Immunohistochemical staining for osteocalcin in the aortic arch (F) and its quantiﬁcation (G). Data represent
means  SD. *P < 0.05.
Figueiredo et alelastolytic activity and cathepsin S protein levels in the aorta
of CRD mice. Cathepsin S is the most potent elastolytic
enzyme. We, therefore, examined elastin fragmentation in
the lesser curvature of aortic arches. We observed that high-
dose RO5444101 treatment (60 mg/kg) signiﬁcantly reduced
the number of elastin ﬁber breaks, as detected by van Gieson
stain (PZ 0.01) (Figure 2, F and G). These results suggested
that mice treated with a high dose of cathepsin S inhibitor had
reduced amounts of cathepsin S and limited elastin breaks,
suggesting that the speciﬁc inhibition of cathepsin S reduces
elastin fragmentation. Fluorescence immunohistochemical
analysis for cathepsin S, mac3, and a-smooth muscle actin in
plaques from CRD mice identiﬁed the cell types responsible
for cathepsin S expression (Figure 2, H and I). We found that
cathepsin S localized predominantly in macrophages but that
some cathepsin S expression was also observed in inﬂamed
medial smooth muscle cells.
Cathepsin S Inhibition Reduces the Development of
Atherosclerotic Plaques and Expression of the
Inﬂammatory Marker GDF15 in CRD Mice
Apoe/ CRD mice treated with the cathepsin S inhibitor
RO5444101 had decreased plaque burden in the lesser1162curvature of the aortic arch (P Z 0.01) (Figure 3, A and
D). The experiments were designed to allow the athero-
sclerotic lesions to develop in Apoe/ mice on a high-fat
high-cholesterol diet for 10 weeks before the induction of
CRD and cathepsin S inhibition for another 10 weeks. To
provide clinically relevant ﬁndings, we examined the
effects of the cathepsin Sespeciﬁc inhibitor RO5444101
on established atherosclerotic plaques but not on the
initiation of atherosclerosis. We clearly observed signiﬁ-
cant reductions in the lesion size (Figure 3D) and
macrophage accumulation (Figure 3E) in Apoe/ CRD
mice treated with a high dose of inhibitor. More impor-
tantly, the treatment reduced the atheroma burden of
Apoe/ CRD mice to levels similar to those of Apoe/
with no CRD. These results suggest that this compound
can substantially retard the development of advanced
atherosclerosis in CRD. To explore the possible mecha-
nisms of plaque size reduction, we examined macrophage
accumulation and activation. RO5444101 treatment
decreased CRD-induced macrophage accumulation and
activation in intima and media as gauged by immuno-
staining for mac3 (P < 0.01 for 6.6 mg/kg, and P < 0.001
for 60 mg/kg) (Figure 3, B and E) and GDF15 (or
macrophage inhibitory cytokine-1; P < 0.0001 for 6.6 andajp.amjpathol.org - The American Journal of Pathology
Figure 5 Cathepsin S (CatS)especiﬁc inhibition by RO5444101 attenuates interferon g (IFN-g)einduced expression of growth differentiation factor-15
(GDF15) and monocyte chemotactic protein-1 (MCP-1)/CCL2 in human and mouse macrophages. Cultured human primary macrophages (MF) differentiated
from peripheral blood monocytes and mouse macrophage-like RAW264.7 cells were pretreated with cathepsin S inhibitor RO5444101 and then were incubated
with IFN-g. RO5444101 or siRNA against cathepsin S reduced IFN-geinduced GDF15 (A) and MCP-1/CCL2 (B) expression in both human and mouse macrophages.
N Z 4 for all experiments. Data represent means  SD. *P < 0.05 between comparisons. Ctrl, control; hIFN-g, human IFN-g; mIFN-g, mouse IFN-g.
Cathepsin S Inhibition in Atherosclerosis60 mg/kg) (Figure 3, C and F). These results indicate that
cathepsin S inhibition can reduce the inﬂammatory burden
and halt and potentially even reverse atherosclerotic
lesion formation in CRD. To demonstrate the cell source
of cathepsin S expression, we performed double immu-
noﬂuorescence labeling of cathepsin S and macrophages
or smooth muscle cells. Staining showed that cathepsin S
is predominantly expressed in medial and intimal mac-
rophages (Figure 2H).Cathepsin S Inhibition Reduces Arterial Calciﬁcation in
CRD Mice
Apoe/ CRD mice treated with 60 mg/kg of RO5444101
did not have signiﬁcantly reduced osteogenic signals in
the carotid arteries (in vivo NIRF imaging) (Figure 4A),
aorta, and brachiocephalic arteries (ex vivo NIRF reﬂec-
tance imaging) (Figure 4, B and C) as detected by the
OsteoSense 680 calcium tracer. However, this treatment
signiﬁcantly lowered alkaline phosphatase activity
(P < 0.01) (Figure 4, D and E) and osteocalcin expression
(P < 0.05) (Figure 4, F and G) in the lesser curvature of
aortic arches compared with the untreated group.
Together, these results demonstrated that mice with CRDThe American Journal of Pathology - ajp.amjpathol.orghave enhanced osteogenic activities, which were reduced
with cathepsin S inhibition.RO5444101 Reduces IFN-geInduced GDF15 Expression
in Human and Mouse Macrophages
The in vivo data suggested that cathepsin Sespeciﬁc inhibition
by RO5444101 reduced macrophage accumulation and
expression of GDF15, a marker for macrophage activation, in
the arteries of Apoe/ CRD mice (Figure 3, B and C). The
next question was whether a decrease in GDF15 resulted from
reduced macrophages or whether this process also involved
decreased macrophage activation. To test the hypothesis that
cathepsin S inhibition reduces GDF15 expression by
decreasing macrophage activation, we performed in vitro
cell culture experiments. RO5444101 pretreatment
reduced GDF15 expression induced by interferon g
(IFN-g) in both human primary macrophages derived from
peripheral blood monocytes (Figure 5A) and mouse
macrophage-like RAW264.7 cells (Figure 5A). The
RO5444101 effect seemed to involve cathepsin S inhibi-
tion, as siRNA silencing of the enzyme also reduced
GDF15 induction by IFN-g (Figure 5A). Similarly,
RO5444101 or cathepsin S silencing by siRNA treatments1163
Figure 6 Cathepsin S inhibition in atherosclerotic plaques in chronic
renal disease. Inhibition of cathepsin S may reduce lesion size via
decreasing growth differentiation factor-15 (GDF15), a modulator of
macrophage chemotaxis. Cathepsin S inhibition also may decrease osteo-
genic stimuli, such as osteopontin and osteocalcin, by suppressing elastin
degradation. CCR2, C-C chemokine receptor type 2.
Figueiredo et alreduced IFN-geinduced expression of monocyte chemo-
tactic protein-1/CCL2, a proinﬂammatory chemokine
(Figure 5B).
Discussion
More than half of all patients with CRD die of cardiovas-
cular causes.1,2 Despite their global health beneﬁts, statins
exert diminished effects in CRD patients.5,6 We, therefore,
need new therapies that alleviate cardiovascular risk in CRD
patients. The present study provides evidence that speciﬁc
and selective inhibition of cathepsin S reduces arterial
inﬂammation and calciﬁcation in mice with CRD, sug-
gesting a novel therapeutic target for reducing CVD risk in
this patient population.
We observed that administration of the selective
cathepsin S inhibitor RO5444101, which does not affect
the proteolytic activity of other cathepsins, ameliorates
several key features of arterial pathology in this animal
model of accelerated atherosclerosis in CRD including i)
reduction of atherosclerotic plaque size; ii) reduction of
macrophage accumulation and activation in atherosclerotic
plaques, as gauged by expression of mac3 and the proin-
ﬂammatory molecule GDF15; iii) reduction of cathepsin
activity and the number of elastin ﬁber breaks in the
atherosclerotic plaques; iv) reduction of osteogenic activ-
ity and some features of vascular calciﬁcation; and v)
reduction of plasma levels of circulating osteogenic
markers. The results of RO5444101 action are summarized
in Figure 6. These results show that elastolysis due to
cathepsin S activity promotes vascular inﬂammation and
calciﬁcation, supporting previous data in cathepsin
Sedeﬁcient mice.21 In addition, the present study results
suggest that maintenance of elastin integrity by selective1164inhibition of cathepsin S activity reduces arterial inﬂammation
and osteogenesis and may improve cardiovascular health in
patients with CRD.
Cathepsin cysteine proteases such as cathepsin S play
key roles in several CVDs, including aneurysm forma-
tion,25 atherosclerosis,26 and vascular calciﬁcation.21
Cathepsin S is one of the most potent cysteine pro-
teases, abundantly expressed by macrophages in
atheroma. In the basal membrane of the blood vessel
wall, cathepsin S acts as a potent elastolytic and colla-
genolytic protease, promoting arterial inﬂammation and
atherosclerosis,21,26 thus making it a promising target for
therapeutic intervention.
We previously reported that genetically modiﬁed
Apoe/ mice lacking cathepsin S with surgically induced
CRD showed signiﬁcantly reduced elastin fragmentation
and calciﬁcation in the arteries and aortic valves.21 In this
compound mutant strain, the expression of other cathep-
sins or matrix metalloproteinases did not change. We thus
proposed that cathepsin S accelerates cardiovascular
calciﬁcation via an elastolysis-dependent mechanism. The
present study has extended previous work into a more
translational investigation. Consistent with ﬁndings on
cathepsin Sedeﬁcient mice, selective cathepsin S inhibi-
tion by administration of novel RO5444101 compound
reduced elastin fragmentation in hypercholesterolemic
Apoe/ mice with CRD. Similarly, RO5444101 also
reduced osteogenic activity in atherosclerotic arteries.
Therefore, suppression of cathepsin S activity through
either genetic or small molecule intervention yields
similar results, lending additional support to a role for
cathepsin S inhibition in the preservation of elastin
integrity and vascular calciﬁcation.
The present study also examined the role of cathepsin
S in atherosclerosis in mice with CRD and found that
selective cathepsin S inhibition signiﬁcantly reduces
atherosclerotic plaque size. This effect likely resulted
from reduced arterial inﬂammation, as we observed
decreased plaque accumulation of macrophages. Macro-
phages promote the initiation and progression of athero-
sclerotic lesions, microcalciﬁcations, plaque rupture, and
acute thrombotic complications.23,27 We reported previ-
ously that fragmentation of elastin ﬁbers promotes
inﬂammation.21 Elastin-derived peptides/fragments exert
proinﬂammatory effects, including macrophage chemo-
attraction18 relevant to vascular pathophysiology.19
Sukhova et al26 reported that cathepsin S genetic dele-
tion reduced atherosclerotic plaque size, macrophage
accumulation, and proinﬂammatory cytokines in hyper-
cholesterolemic low-density lipoprotein receptoredeﬁcient
mice. The present study observed similar ﬁndings in
hypercholesterolemic apolipoprotein Eedeﬁcient mice
with CRD suggesting that the presence of CRD, while
accelerating atherosclerosis and inducing arterial calciﬁ-
cation, did not negate the atheroprotective effects of
cathepsin S inhibition.ajp.amjpathol.org - The American Journal of Pathology
Cathepsin S Inhibition in AtherosclerosisGDF15/macrophage inhibitory cytokine-1 is a member
of the transforming growth factor b superfamily and
recently was recognized as a novel biomarker associated
with CVD in the general population28 and in patients with
CRD.29 Herein, we localized GDF15 protein in mac3-
positive macrophages, and cathepsin S inhibition signiﬁ-
cantly reduced GDF15 accumulation in aortic lesions.
Validation studies in vitro using primary macrophages
and immortalized macrophage cell lines demonstrated that
either cathepsin S inhibitor or siRNA reduced IFN-
geinduced macrophage GDF15 expression, consistent
with the in vivo data. Therefore, GDF15, a known inducer
of macrophage activation,30 may contribute to the proin-
ﬂammatory role of cathepsin S. Because GDF15 also
independently predicts mortality risk in patients with
CRD,29 it may link atherosclerotic lesion development
and CRD. GDF15 modulates macrophage chemotaxis in a
strict C-C chemokine receptor type 2 and transforming
growth factor b receptor type IIedependent manner.31 We
thus examined the effects of cathepsin S inhibition on
CCL2da C-C chemokine receptor type 2 liganddand
found that cathepsin S inhibition reduces macrophage
expression of CCL2. Therefore, selective cathepsin S in-
hibition may inhibit macrophage recruitment in athero-
sclerotic lesions and reduce vascular inﬂammation and
plaque development.
Complex positive feedback loops involving multifunc-
tional regulators, such as cathepsin S, typically accelerate
inﬂammation. It is, therefore, difﬁcult to distinguish the
direct effects of cathepsin S inhibition from secondary
consequences in vivo. In addition to effects on macro-
phages and GDF15, this inhibitor reduces the surface
major histocompatibility complex class II levels and the
antigen-induced cytokine response in PBMCs. Moreover,
gene deletion and pharmacological inhibition experiments
in rodents demonstrate that cathepsin S participates in
other cell types or contexts, such as reduced immune
response of CD4þ T cells and lower mobility of dendritic
cells and B cells.32,33 These mechanisms support cathepsin
S as an attractive therapeutic target for immune diseases
other than atherosclerosis, such as multiple sclerosis and
rheumatoid arthritis.
In conclusion, the signiﬁcantly elevated risk of cardiovas-
cular morbidity and mortality in patients with CRD persisting
after statin treatment calls for new therapeutic targets for
intervention. Herein, we extend a previous mouse genetics
study that demonstrated the impact of cathepsin S on cardio-
vascular inﬂammation and calciﬁcation by providing clinically
translatable evidence. These ﬁndings support selective
cathepsin S inhibition as a novel solution that may halt the
progression of inﬂamed atherosclerotic lesions and prevent
devastating cardiovascular complications in patients with
CRD. Ongoing efforts that combine delineation of underlying
molecular mechanisms and rigorous assessment of the
cathepsin S inhibitor in patients will provide new insight into
the optimal management of CVD in CRD patients.The American Journal of Pathology - ajp.amjpathol.orgAcknowledgments
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